Shanghai Henlius Biotech’s Privatization by Fosun Advances

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.

Shanghai Henlius Biotech is undergoing a pre-conditional privatization led by Fosun New Medicine, aiming to merge and absorb the company. The merger is progressing as the Offeror liaises with Chinese authorities to meet necessary pre-conditions. A delay in the dispatch of the composite document has been announced, with a new deadline set for May 2025.

For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.